HANGZHOU, Aug 19, 2022 - (ACN Newswire via SEAPRWire.com) - New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today.Based on the financial information before the audit as of June 30, 2022, New Horizon Health achieved total revenue of RMB226 million in the first half of 2022, an increase of 414% over the same period in 2021; achieved a gross profit of RMB185 million, an increase of 650% over the same period in 2021; gross profit margin climbed to 82.0% from 56.2% in the first half of 2021. The Company's adjusted net loss for the half-year was RMB106 million and the adjusted net loss rate(1) narrowed significantly from 221% to 47%; the ratio of expenses to sales(1) dropped significantly from 161% to 86%, and the ratio of management expense to sales(1) dropped significantly from 80% to 23%. The Company's total cash, including time deposits, cash, and cash equivalents, amounted to RMB1.65 billion.The Company announced its cervical cancer screening product, CerviClear(TM), which had been launched in a large-scale prospective multi-center registered clinical trial in June 2022. ...